Health Care [ 12/12 ] | Biotechnology [ 64/73 ]
NASDAQ | Common Stock
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases.
Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa; and RPIDD, a liquid biopsy rapid pathogen diagnostic which is in preclinical trial to treat pathogen molecular diagnostics.
The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections.
In addition, it is developing NLS-1, which is in preclinical trial for the treatment of endometriosis; DLS-1+2, which is in preclinical trial to treat NSCLC with mutation; DLS-3, which is in preclinical trial to treat autoimmune disease; CLS-1, a macromolecule, which is in preclinical trial to treat obesity; and CLS-1 and CLS-3.
Further, the company offers NativusWell DOI (NLS-2), a dietary supplement for women undergoing menopause; and provides management services.
The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017.
Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 30, 25 | -0.29 Decreased by -16.00% | - |
| Dec 20, 24 | -0.50 Decreased by -6.38% | - |
| Apr 28, 23 | -2.22 Decreased by -684.21% | - |
| Sep 30, 22 | -0.05 Increased by +78.69% | -3.00 Increased by +98.33% |
| Apr 29, 22 | -0.25 Decreased by -232.35% | -3.30 Increased by +92.42% |
| Sep 15, 21 | -0.47 Decreased by -123.81% | -3.00 Increased by +84.33% |
| Apr 19, 21 | 0.38 Increased by +215.15% | -3.10 Increased by +112.26% |
| Mar 31, 21 | -0.23 Decreased by -126.45% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | N/A Decreased by -100.00% | -1.62 M Increased by +79.48% | - - |
| Sep 30, 24 | N/A Decreased by -100.00% | -2.64 M Decreased by -40.27% | - - |
| Mar 31, 24 | N/A Increased by +100.00% | 2.66 M Increased by +219.75% | - - |
| Sep 30, 23 | 431.38 K Decreased by -32.36% | -5.49 M Increased by +65.88% | Decreased by -1.27 K% Increased by +49.55% |
| Mar 31, 23 | 768.43 K Decreased by -96.73% | -7.91 M Decreased by -126.55% | Decreased by -1.03 K% Decreased by -911.40% |
| Jun 30, 22 | 527.46 K Increased by +61.17% | -1.89 M Increased by +69.62% | Decreased by -357.37% Increased by +81.15% |
| Mar 31, 22 | -1.25 M Decreased by -524.87% | -2.22 M Increased by +76.84% | Increased by +177.14% Increased by +105.45% |
| Jun 30, 21 | 637.78 K Increased by +165.97% | -16.08 M Decreased by -76.95% | Decreased by -2.52 K% Increased by +33.47% |